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a b s t r a c t
Dietary intervention studies suggest that ﬂavan-3-ol intake can improve vascular function and reduce
the risk of cardiovascular diseases (CVD). However, results from prospective studies failed to show a
consistent beneﬁcial effect. Associations between ﬂavan-3-ol intake and CVD risk in the Norfolk arm of
the European Prospective Investigation into Cancer and Nutrition (EPIC-Norfolk) were investigated. Data
were available from 24,885 (11,252 men; 13,633 women) participants, recruited between 1993 and 1997
into the EPIC-Norfolk study. Flavan-3-ol intake was assessed using 7-day food diaries and the FLAVIOLA
Flavanol Food Composition database. Missing data for plasma cholesterol and vitamin C were imputed
using multiple imputation. Associations between ﬂavan-3-ol intake and blood pressure at baseline were
determined using linear regression models. Associations with CVD risk were estimated using Cox
regression analyses. Median intake of total ﬂavan-3-ols was 1034 mg/d (range: 0–8531 mg/d) for men
and 970 mg/d (0–6695 mg/d) for women, median intake of ﬂavan-3-ol monomers was 233 mg/d (0–
3248 mg/d) for men and 217 (0–2712 mg/d) for women. There were no consistent associations between
ﬂavan-3-ol monomer intake and baseline systolic and diastolic blood pressure (BP). After 286,147
person-years of follow-up, there were 8463 cardiovascular events and 1987 CVD related deaths; no
consistent association between ﬂavan-3-ol intake and CVD risk (HR 0.93, 95% CI: 0.87; 1.00; Q1 vs Q5) or
mortality was observed (HR 0.93, 95% CI: 0.84; 1.04). Flavan-3-ol intake in EPIC-Norfolk is not sufﬁcient
to achieve a statistically signiﬁcant reduction in CVD risk.
& 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
The medicinal use of ﬂavan-3-ols and proanthocyanidins has a
long documented history [1] and as early as 1590 in the Florentine
Codex [2], cacao beans, a major source of ﬂavanols, were recom-
mended to treat heart disease [3]. In recent decades, there has
been an increasing interest in the physiological effects of ﬂavan-3-
ols on vascular function. While their vasculoprotective properties
were at ﬁrst attributed to their activity as antioxidants in vitro [4],
recent research has shown that this is unlikely [5] and that the
modulation of arterial function of ﬂavan-3-ols is based on a nitric
oxide-dependent mechanism [6–8].
Dietary intervention studies with different sources of ﬂavan-3-
ols, such as cocoa ﬂavanols [9–11] or grape seed extracts [12], have
shown a potentially beneﬁcial effect on vascular function. How-
ever, data from observational studies are more ambiguous. Data
from anthropological research in a population with high habitual
intake of cocoa, the Kuna of Panama, suggest that ﬂavan-3-ol
intake can improve vascular function [13], but results from the
Nurses Health Studies and Health Professionals Follow-up Study
[14–16], the Iowa Women's Health Study [17], the Cancer Prevention
Study [18], and the Zutphen Elderly Study [19] have not shown any
consistent associations between ﬂavan-3-ol intake and CVD risk or
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risk factors such as blood pressure. Studies investigating associa-
tions between CVD risk and intake of ﬂavan-3-ol-rich foods, in
particular chocolate, did show beneﬁcial effects [20–22], but the
ﬂavan-3-ol contribution from chocolate in the European popula-
tion is very small [23] and it is likely that self-reported chocolate
consumption acts mainly as a surrogate marker for a yet uni-
dentiﬁed factor.
The results from intervention studies suggest that ﬂavan-3-ols
can reduce the risk for CVD. This is of great importance in the
context of public health, as CVDs are responsible for approximately
30% of all deaths globally [24]. However, the ambiguity of results
from observational studies raises several questions, in particular
how the apparent contradiction with intervention studies can be
explained and whether these data can be easily translated to the
general public.
The primary objective of this study was to investigate associa-
tions between ﬂavan-3-ol intake and CVD risk in the Norfolk arm
of the European Prospective Investigation into Cancer and Nutrition
(EPIC-Norfolk), and to compare these results with data from
previous studies as well as dietary intervention studies in the
context of primary prevention of CVD. The EPIC-Norfolk cohort is
particularly well placed to investigate these associations, as it has
the widest range and highest intake of ﬂavan-3-ol intake among
all EPIC cohorts [25] and a wider range of intake than cohorts
investigated previously. Furthermore, we have assessed intake
using 7-day-diaries (7DD) and a newly developed food composi-
tion database [23], which provide a more accurate estimate of
dietary intake.
Subjects and methods
Study population
Between 1993 and 1997, approximately 30,000 men and
women between 40 and 75 years were recruited for the European
Prospective Investigation into Cancer and Nutrition (EPIC) Norfolk
study from a general practitioners' database [26]. The 25,639
participants attended a health examination. Diet was assessed by
7DD. The ﬁrst day of the diary was completed as a 24-h recall
(24HDR) with a trained interviewer and the remainder completed
during subsequent days. Diary data were entered using the in-
house dietary assessment software DINER—Data into Nutrients for
Epidemiological Research [27]; data were checked and calculated
using DINERMO [28]. Health and lifestyle characteristics, including
data on smoking, alcohol consumption, social class, family medical
history, exercise, and reproductive history, were assessed by
questionnaire. Height and weight measurements were collected
following a standardized protocol as part of a health check
conducted by trained research nurses. Physical activity, represent-
ing occupational and leisure activity, was assessed using a vali-
dated questionnaire [29]. Blood pressure was measured by using a
noninvasive oscillometric blood pressure monitor (Acutorr; Data-
scope Medical, Huntingdon, UK) after the participant had been
seated in a comfortable environment for 5 min. The arm was
horizontal and supported at the level of the mid-sternum; the
mean of two readings was used for analysis. Acutorr readings were
checked against those from sphygmomanometers every 6 months.
The study was approved by the Norwich District Health Authority
Ethics Committee, and all participants gave signed informed
consent.
Nonfasting blood samples were taken by vein puncture at
baseline health check and stored in serum tubes. Serum levels of
total cholesterol were measured on fresh samples with the RA
1000 autoanalyzer (Bayer Diagnostics, Basingstoke, UK). Plasma
vitamin C was measured using a ﬂuorometric assay as described
previously [30]. Baseline data for 25,639 participants (11,607 men;
14,032 women) were available. Participants with data processing
errors (4 men), incidence date before the start of the study (10
men; 4 women), and missing dietary data (73 men; 62 women)
were excluded. Furthermore, participants with self-reported
energy intake in the bottom (p1) or top (p99) sex-speciﬁc perce-
ntile (men, 4.6 MJ–15.3 MJ; women, 3.5 MJ–11.4 MJ) (230 men;
279 women), missing BMI (20 men; 23 women), and missing
endpoint data (systolic blood pressure; 24 men; 36 women) were
excluded, resulting in a sample size of 24,885 (11,252 men; 13,633
women; see also Fig. 1).
Incident CVD event and mortality
The primary endpoint of this study was any ﬁrst CVD event
(deﬁned as ICD 410–448 (ICD 9) or ICD I10–I79 (ICD 10), which
includes coronary heart disease (410–414 (ICD 9) or I20–I25 (ICD
10)), stroke (430–438 (ICD 9) or I60–I69 (ICD 10)), and cardiac
failure (428 (ICD 9) or I50 (ICD 10)) and other vascular causes)
during follow-up. All participants were followed up for fatal and
nonfatal CVD events, and the present study includes events until
31 March 2009, covering 11.173.7 years (mean7SD) of follow up.
Cause-speciﬁc hospital admission was determined via ENCORE
(East Norfolk Commission Record, the hospital admissions data-
base kept by the East Norfolk Health Commission) [31] with the
individuals' unique National Health Service number. All indivi-
duals were ﬂagged by the UK Ofﬁce of National Statistics (ONS) for
death certiﬁcation and trained nosologists coded death certiﬁcates
according to the International Classiﬁcation of Disease (ICD). Death
certiﬁcates and ENCORE show high accuracy in correctly identify-
ing incident disease, as previously shown in EPIC-Norfolk for
incident stroke [31].
Flavan-3-ol intake
We estimated ﬂavan-3-ol intake by using the FLAVIOLA Flavanol
Food Composition database, which was developed for the FLAVIOLA
project [23]. The database contains food composition data for
approximately 3000 food items and is based on the US Depart-
ment of Agriculture database for the Flavonoid Content of Selected
Foods [32] and the Proanthocyanidins (PA) Content of Selected
Foods [33], expanded with values from Phenol-Explorer, a com-
prehensive database on the polyphenol content of foods [34].
These databases are the most up-to-date databases on ﬂavonoids
and polyphenols, and include information for 500, 205, and 456
food items for ﬂavonoids [32], PA [33], and polyphenols [34],
Fig. 1. Study population and exclusion criteria.
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respectively. On the basis of these data, we determined the ﬂavan-
3-ol content of foods by substitution and calculations to reﬂect
edible portions, food preparation methods, and recipe break down
(see [35] for the methodology). Flavan-3-ol intake was determined
for the following groups of ﬂavan-3-ols (Table 1): ﬂavan-3-ols
monomers [()-epicatechin, ()-epicatechin-3-gallate, (þ)-cate-
chin, ()-epigallocatechin, ()-epigallocatechin-3-gallate, (þ)-gal-
locatechin, (þ)-catechin-3-gallate], theaﬂavins (theaﬂavin, thearu-
bigins, theaﬂavin-3,30-digallate, theaﬂavin-30-gallate, theaﬂavin-3-
gallate), and PA (dimers, trimers, 4–6 mers, 7–10 mers, 410 mers).
Data analysis
Missing data
Supplemental Table 1 shows a summary of missing data. For
categorical data, an additional value of “missing” was created. For
continuous variables (cholesterol and plasma vitamin C), missing
values were assumed to be missing at random and were imputed
using multiple imputation (n¼5) with univariate regression
models.
Descriptive statistics
Descriptive characteristics of the study population were sum-
marized using mean (plus or minus standard deviation) for
normally distributed continuous variables, frequency and percen-
tages for categorical variables, and geometric means (standard
deviation) for nonnormally distributed continuous variables.
Association between ﬂavan-3-ol intake and blood pressure
Associations between ﬂavan-3-ol intake and systolic blood
pressure were investigated using linear regression models; dietary
intake data were divided into sex-speciﬁc quintiles. Log-trans-
formed values were used for the dependent variable (systolic
blood pressure), as well as for BMI (body weight/height2 in kg/m2)
and the intake of energy, sodium, potassium, fat, and saturated fat.
In initial analyses (model 1), intake was adjusted by age, BMI (kg/
m2) and energy intake (kJ/d (day)). A parsimonious model was
developed using a stepwise selection approach (only covariables
with a P valueo0.2 were included in the model) using the
following covariables: BMI (kg/m2), energy intake (kJ/d), plasma
vitamin C (mmol/L), ﬁber, total fat and saturated fat consumptions
(g/day), and alcohol consumption (0 g/d, o15 g/d, Z15 g/d) and
the following categorical variables—physical activity (inactive,
moderately inactive, moderately active, active), smoking status
(former, current, never), social class (professional, managerial,
skilled (manual/nonmanual), semiskilled, unskilled), marital status
(single, married, widowed, divorced, separated), education (none,
O-level, A-level, degree), self-reported history of stroke, myocar-
dial infarction and diabetes at baseline, family history of myocardial
infarction, use of antihypertensive and lipid lowering drugs; addi-
tionally in women hormone replacement therapy (current, former,
never) and menopausal status (pre, peri, and post). The parsimonious
model included age, BMI, energy intake, plasma vitamin C, dietary
intake of ﬁber, fat, saturated fat, and alcohol and the following
categorical variables: physical activity, smoking status, marital status,
education, use of antihypertensive drugs, and self-reported history of
stroke, myocardial infarction, and diabetes at baseline, family history
of myocardial infarction and—for women—menopausal status and
hormone replacement therapy. Tests for linear trend were conducted
by including the median value of each quintile in the model.
Association between ﬂavan-3-ol intake and CVD risk
Associations between quintiles of ﬂavan-3-ol intake and CVD
risk and mortality were analyzed using a Cox regression analysis to
investigate hazard ratios and 95% conﬁdence intervals. Log-
transformed values were used for systolic blood pressure, BMI,
and the intakes of energy, sodium, potassium, fat, and saturated
fat. Associations were ﬁrst analyzed adjusting for BMI and energy
intake only. A parsimonious model was then developed as
described above, and it included the following variables: BMI,
energy intake, systolic blood pressure, plasma cholesterol, plasma
vitamin C, intake of ﬁber, potassium, sodium, fat, saturated fat, and
alcohol, and the following categorical variables—physical activity,
smoking status, education, self-reported history of stroke, myo-
cardial infarction and diabetes at baseline, family history of
myocardial infarction, use of antihypertensive and lipid lowering
drugs; additionally in women use of hormone replacement ther-
apy. Tests for linear trend were conducted by including the median
value of each quintile in the model.
Sensitivity analyses
In post hoc sensitivity analyses, we investigated associations in
participants healthy at baseline (no self-reported use of antihy-
pertensive drugs, no self-reported incidence of diabetes mellitus,
myocardial infarction, or stroke), those at high risk of CVD (10-year
CVD risk 20% higher than normal based on Framingham risk score
[36]) and those with at least 3 days of dietary data.
Strobe checklist
The STROBE checklist for cohort studies [37] has been com-
pleted for this study.
Statistical analyses
All analyses were conducted with Stata (version 11 for Mac OS
X; Stata Corp, College Station, TX, USA).
Results
Study population and ﬂavan-3-ol monomer intake
Data were available for 11,252 men and 13,633 women, 8176 of
which were postmenopausal. Baseline characteristics of the cohort
and dietary information by sex-speciﬁc quintile of ﬂavan-3-ol
monomer intake are shown in Supplemental Table 2. Mean age of
the participants at baseline was 59 years (range: 39–79 years) for
men and 58 years (39–78 years) for women. Median intake of total
ﬂavan-3-ols was 1034 mg/d (0–8531 mg/d) for men and 970 mg/d
(0–6695 mg/d) for women; median intake of ﬂavan-3-ol monomers
was 233 mg/d (0–3248 mg/d) for men and 217 (0–2712 mg/d) for
women (see Table 2 for more details). While there were signiﬁcant
differences in many baseline characteristics between sex-speciﬁc
quintiles of ﬂavan-3-ol monomer intake, these differences did not
follow a consistent trend.
Table 1
Deﬁnition of different types of ﬂavan-3-ols used in this study.
Flavan-3-
ols
Flavan-3-ol
Monomer
Cocoa
ﬂavanols
()-Epicatechin X X X
(þ)-Catechin X X X
Gallated formsa X X X
Proanthocyanidins X Xb
Thearubigins and
Theaﬂavinsc
X
a Epicatechin-30-gallate, epigallocatechin, epigallocatechin-30-gallate, galloca-
techin, catechin-30-gallate.
b Includes only proanthocyanidins up to a degree of polymerization of 10.
c Theaﬂavin, thearubigins, theaﬂavin-3,30-digallate, theaﬂavin-30-gallate, thea-
ﬂavin-3-gallate.
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The relative composition of dietary ﬂavan-3-ol intake was consis-
tent in the top four quintiles of ﬂavan-3-ol intake (Q2 to Q5), with
gallated compounds being the main contributor to total intake of
monomers (Fig. 2; the same pattern was observed for women and
postmenopausal women) and theaﬂavins the main type of oligomeric
ﬂavan-3-ols. However, in participants with low ﬂavan-3-ol intake (Q1),
()-epicatechin and (þ)-catechin were the main sources of ﬂavan-3-
ol monomers and proanthocyanidins the main type of oligomeric
ﬂavan-3-ols consumed. It was also noticeable that the relative compo-
sition of dietary ﬂavan-3-ols was more variable in the bottom quintile.
Associations among ﬂavan-3-ol intake, CVD risk, and mortality
In women, ﬂavan-3-ol intake was not associated with CVD risk
or mortality and these results were consistent when using different
models and also in sensitivity analyses (Table 3). In men, ﬂavan-3-ol
intake was not associated with mortality and the risk of stroke.
However, the association between ﬂavan-3-ol intake and both IHD
risk and total CVD risk was more complex and followed a J-shaped
curve: low and medium intake (Q2 and Q3) were both associated
with a reduced risk. The risk estimates for quintiles two to ﬁve of
ﬂavan-3-ol intake were not signiﬁcantly different and there was no
linear trend.
Post hoc sensitivity analyses with healthy individuals, indivi-
duals with a raised 10-year CVD risk, and those with at least 3 days
of diary data showed no materially different associations. In sens-
itivity analyses, we investigated the association between spe-
ciﬁc groups of ﬂavan-3-ols and CVD risk: no material differences
were observed between different types of ﬂavan-3-ols (Fig. 3).
Associations between ﬂavan-3-ol intake and blood pressure
Supplemental Table 4 shows the results of regression analyses
between ﬂavan-3-ol intake and systolic and diastolic blood pres-
sure (log-transformed) at baseline. There were no consistent
signiﬁcant association between ﬂavan-3-ol intake and baseline
blood pressure.
Discussion
The EPIC-Norfolk cohort is well positioned for a detailed
investigation of the association between ﬂavan-3-ol intake and
CVD risk, in particular because of the prospective design of the
study, the wide range of ﬂavan-3-ol intake, and the detailed
dietary information available from 7-day diet diaries. In combina-
tion with the newly developed FLAVIOLA Flavanol Food Composition
Database, this provides the most accurate estimate of ﬂavan-3-ol
consumption in a prospective cohort currently available. There are
some limitations, in particular the known limitations of self-
reported dietary assessment and the accuracy of phytochemical
intake based on food composition tables. We have also conducted
multiple comparisons without adjustment, which should be con-
sidered when interpreting results.
The estimated ﬂavan-3-ol monomer intake in this study was
higher than in comparable studies conducted previously
(Supplemental Table 4). Despite the wider range of intake, we
have not found any consistent association between ﬂavan-3-ol
monomer intake and systolic blood pressure at baseline or risk of
CVD, and our data are corroborated by results from previous
studies [15,17,18,20,38] (Fig. 4 and Supplemental Table 4).
It was noticeable that the association between ﬂavan-3-ol intake
and CVD risk followed a J-shaped curve with the lowest relative risk
in quintile 2, and this pattern has also been observed in previous
studies [15,17,18]. Our data show differences in the relative compo-
sition of ﬂavan-3-ols consumed between those in the bottom
quintile of intake and other participants (Fig. 2). While data on
ﬂavan-3-ol composition in the bottom quintile should be inter-
preted carefully, because of the error associated with the assess-
ment of such small amounts, it is likely that this difference in
relative ﬂavan-3-ol composition is an explanation for the J-shaped
associations we observed.
The absence of consistent statistically signiﬁcant associations
between ﬂavan-3-ol intake and CVD risk is noteworthy in light of
data from dietary intervention studies, which suggest vasculopro-
tective effects of dietary ﬂavan-3-ols. Indeed, several meta-analyses
have shown a signiﬁcant reduction in systolic blood pressure (3 to
5 mm Hg) for interventions with cocoa ﬂavanols [10,11] and smaller
reductions with other ﬂavan-3-ol-rich foods such as tea [39] or
grape seed extract [40]. A reduction of systolic blood pressure by
3 to 5 mm Hg is comparable to the effect that could be achieved by
Table 2
Baseline characteristics (mean and SD) and baseline intake (median and range) of
11,252 men and 13,633 women in EPIC-Norfolk.
Men Women Postmenopausal women
n 11252 13633 8176
Age [years] 59 (9) 58 (9) 64 (7)
BMI [kg/m2] 27 (3) 26 (4) 27 (4)
Cholesterol
[mmol/L]
6.0 (1.1) 6.3 (1.2) 6.6 (1.2)
Systolic BP
[mm Hg]
137.5 (17.7) 134.0 (18.9) 137.5 (17.7)
Diastolic BP
[mm Hg]
84.4 (11.1) 81.0 (11.1) 82.8 (11.2)
Flavan-3-ol
intake in mg/d
Flavan-3-ols 1034 (0–8531) 970 (0–6695) 981 (0–6695)
Flavan-3-ol
monomers
233 (0–3248) 217 (0–2712) 219 (0–2712)
Epicatechin 27 (0–225) 25 (0–198) 25 (0–198)
Catechin 20 (0–108) 18 (0–84) 17 (0–84)
Gallated
compounds
183 (0–2936) 172 (0–2453) 176 (0–2453)
Proanthocyanidinsa 138 (0–2082) 136 (0–1403) 134 (0–1359)
Theaﬂavins 644 (0–6095) 601 (0–4876) 612 (0–4876)
Cocoa ﬂavanolsb 154 (0–1561) 144 (0–1118) 142 (0–1060)
a With a degree of polymerization of two and above.
b ()-Epicatechin, (þ)-catechin, and proanthocyanidins with a degree of
polymerization of 2 to 10.
Fig. 2. Relative composition of total dietary ﬂavan-3-ols by ﬂavan-3-ol monomer
intake in male participants of EPIC-Norfolk (results for women and postmenopau-
sal women are similar). ()-Epicatechin and (þ)-catechin were the main con-
tributors of total monomer intake in the bottom quintile, while gallated
compounds were the main contributor to monomer intake in the top four quintiles.
For concomitantly consumed nonmonomeric ﬂavanols, similar differences were
observed. In the bottom quintile, proanthocyanidins were the dominant class of
compounds, while in the other quintiles, theaﬂavins were more important.
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Table 3
Association between ﬂavan-3-ol intake and risk of CVD and mortality: Hazard ratio and 95% conﬁdence interval a
Q1 Q2 Q3 Q4 Q5 pTrend
Men (n¼11,252)
CVD Incidence
(4403)
Person-Years (all men) 25291 24964 24980 24466 25001
Incidents (all men) 800 878 898 952 875
Model 1b 1 0.89 (0.81; 0.98) 0.84 (0.77; 0.93) 0.99 (0.90; 1.09) 0.97 (0.88; 1.07) 0.678
Model 2c 1 0.87 (0.79; 0.96) 0.81 (0.74; 0.90) 0.91 (0.83; 1.00) 0.90 (0.81; 0.99) 0.176
– healthy at baselined (n¼8636) 1 0.86 (0.76; 0.97) 0.79 (0.70; 0.90) 0.98 (0.86; 1.10) 0.89 (0.78; 1.01) 0.427
– high riske (n¼8010) 1 0.85 (0.77; 0.95) 0.80 (0.72; 0.89) 0.87 (0.78; 0.97) 0.91 (0.82; 1.02) 0.270
– at least 3 days diary (n¼10,343) 1 0.85 (0.77; 0.94) 0.82 (0.75; 0.91) 0.91 (0.83; 1.01) 0.91 (0.82; 1.01) 0.329
IHD Incidence
(2335)
Person-Years 27351 27293 27371 26872 27413
Incidents 425 456 459 531 464
Model 1b 1 0.89 (0.78; 1.02) 0.84 (0.74; 0.96) 1.06 (0.93; 1.20) 0.99 (0.87; 1.13) 0.309
Model 2c 1 0.85 (0.74; 0.97) 0.81 (0.71; 0.93) 0.94 (0.83; 1.08) 0.88 (0.77; 1.01) 0.338
– healthy at baselined (n¼8636) 1 0.84 (0.70; 1.02) 0.75 (0.62; 0.91) 1.07 (0.89; 1.28) 0.97 (0.80; 1.17) 0.443
– high riske (n¼8010) 1 0.81 (0.70; 0.93) 0.80 (0.69; 0.92) 0.85 (0.74; 0.98) 0.86 (0.74; 1.00) 0.161
– at least 3 days diary (n¼10,343) 1 0.85 (0.74; 0.98) 0.85 (0.74; 0.98) 0.97 (0.84; 1.11) 0.94 (0.81; 1.08) 1.000
Stroke Incidence
(5 9 5)
Person-Years 29575 29515 29613 29686 29614
Incidents 89 123 135 117 131
Model 1b 1 0.99 (0.75; 1.30) 0.99 (0.75; 1.29) 0.94 (0.71; 1.24) 1.18 (0.90; 1.54) 0.263
Model 2c 1 0.99 (0.75; 1.31) 0.98 (0.75; 1.29) 0.88 (0.66; 1.17) 1.08 (0.82; 1.43) 0.727
– healthy at baselined (n¼8636) 1 1.13 (0.78; 1.64) 1.00 (0.68; 1.45) 1.04 (0.71; 1.52) 1.10 (0.75; 1.62) 0.765
– high riske (n¼8010) 1 0.96 (0.72; 1.30) 0.94 (0.70; 1.26) 0.89 (0.66; 1.20) 1.15 (0.85; 1.54) 0.388
– at least 3 days diary (n¼10,343) 1 0.87 (0.66; 1.15) 0.86 (0.66; 1.13) 0.79 (0.60; 1.05) 0.95 (0.71; 1.25) 0.670
CVD mortality
(1154)
Person-Years 27854 27415 27550 27495 27533
Incidents 173 243 264 250 224
Model 1b 1 1.00 (0.80; 1.26) 0.96 (0.77; 1.21) 1.07 (0.85; 1.34) 1.07 (0.85; 1.35) 0.428
Model 2c 1 0.98 (0.78; 1.23) 0.94 (0.75; 1.19) 0.94 (0.75; 1.18) 0.95 (0.74; 1.20) 0.607
– healthy at baselined (n¼8636) 1 1.15 (0.79; 1.68) 1.10 (0.76; 1.59) 1.44 (1.00; 2.07) 1.26 (0.86; 1.84) 0.123
– high riske (n¼8010) 1 1.04 (0.81; 1.32) 0.95 (0.74; 1.21) 0.96 (0.75; 1.23) 1.00 (0.78; 1.29) 0.852
– at least 3 days diary (n¼10,343) 1 0.91 (0.72; 1.15) 0.90 (0.72; 1.14) 0.93 (0.73; 1.17) 0.93 (0.73; 1.18) 0.677
All cause
mortality
(3244)
Person-Years 27854 27415 27550 27495 27533
Incidents 538 653 690 685 678
Model 1b 1 0.90 (0.79; 1.04) 0.85 (0.74; 0.97) 0.93 (0.81; 1.06) 1.03 (0.90; 1.18) 0.373
Model 2c 1 0.91 (0.80; 1.05) 0.87 (0.76; 1.00) 0.90 (0.78; 1.03) 0.99 (0.86; 1.14) 0.946
– healthy at baselined (n¼8636) 1 1.00 (0.83; 1.21) 0.99 (0.82; 1.19) 1.07 (0.89; 1.28) 1.16 (0.97; 1.40) 0.065
– high riske (n¼8010) 1 0.92 (0.79; 1.06) 0.86 (0.74; 1.00) 0.87 (0.75; 1.01) 1.01 (0.86; 1.17) 0.894
– at least 3 days diary (n¼10,343) 1 0.88 (0.76; 1.01) 0.84 (0.73; 0.97) 0.91 (0.79; 1.04) 0.99 (0.86; 1.14) 0.709
Women (n¼13,633)
CVD Incidence
(4060)
Person-Years 32794 32236 31938 31954 32524
Incidents 678 824 905 874 779
Model 1b 1 0.98 (0.89; 1.09) 1.01 (0.92; 1.12) 1.09 (0.98; 1.21) 1.11 (1.00; 1.23) 0.009
Model 2c 1 0.96 (0.86; 1.06) 0.97 (0.87; 1.07) 1.04 (0.94; 1.16) 1.01 (0.91; 1.13) 0.364
– healthy at baselined (n¼10,795) 1 1.06 (0.92; 1.21) 0.97 (0.85; 1.11) 1.04 (0.91; 1.19) 1.12 (0.98; 1.28) 0.138
– high riske (n¼8507) 1 0.93 (0.83; 1.04) 0.95 (0.85; 1.06) 1.04 (0.93; 1.16) 0.96 (0.86; 1.08) 0.884
– at least 3 days diary (n¼12,815) 1 0.94 (0.85; 1.05) 0.96 (0.87; 1.06) 1.04 (0.93; 1.15) 1.01 (0.91; 1.13) 0.373
IHD incidence
(1325)
Person-Years 35139 35167 35094 34897 35275
Incidents 207 269 306 313 230
Model 1b 1 1.01 (0.84; 1.22) 1.09 (0.91; 1.30) 1.25 (1.05; 1.50) 1.09 (0.91; 1.32) 0.076
Model 2c 1 1.00 (0.83; 1.20) 1.06 (0.88; 1.27) 1.16 (0.97; 1.39) 0.96 (0.80; 1.17) 0.810
– healthy at baselined (n¼10,795) 1 1.15 (0.89; 1.49) 0.98 (0.76; 1.27) 1.20 (0.93; 1.54) 1.06 (0.81; 1.38) 0.648
– high riske (n¼8507) 1 1.01 (0.83; 1.23) 1.03 (0.85; 1.25) 1.20 (0.99; 1.45) 0.97 (0.78; 1.19) 0.748
– at least 3 days diary (n¼12,815) 1 1.04 (0.86; 1.25) 1.07 (0.89; 1.29) 1.20 (1.00; 1.45) 0.98 (0.80; 1.19) 0747
Stroke incidence
(6 0 5)
Person-Years 35935 35994 36089 36022 36005
Incidents 96 132 140 129 108
Model 1b 1 0.96 (0.73; 1.25) 0.91 (0.70; 1.18) 0.95 (0.73; 1.25) 1.03 (0.78; 1.36) 0.806
Model 2c 1 0.94 (0.72; 1.23) 0.86 (0.66; 1.12) 0.88 (0.67; 1.16) 0.89 (0.68; 1.19) 0.384
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Table 3 (continued )
Q1 Q2 Q3 Q4 Q5 pTrend
– healthy at baselined (n¼10,795) 1 1.00 (0.69; 1.44) 0.96 (0.67; 1.38) 1.00 (0.69; 1.44) 1.01 (0.69; 1.48) 0.958
– high riske (n¼8507) 1 0.93 (0.70; 1.24) 0.82 (0.62; 1.09) 0.83 (0.62; 1.11) 0.91 (0.68; 1.23) 0.393
– at least 3 days diary (n¼12,815) 1 0.91 (0.69; 1.19) 0.86 (0.66; 1.13) 0.87 (0.66; 1.15) 0.91 (0.68; 1.21) 0.502
CVD mortality
(8 3 3)
Person-Years 3479 34597 34801 34652 35037
Incidents 138 173 188 193 141
Model 1b 1 0.95 (0.73; 1.25) 0.84 (0.64; 1.11) 0.98 (0.75; 1.28) 0.93 (0.70; 1.25) 0.734
Model 2c 1 0.92 (0.70; 1.21) 0.78 (0.60; 1.03) 0.89 (0.67; 1.17) 0.81 (0.60; 1.09) 0.166
– healthy at baselined (n¼10,795) 1 1.02 (0.69; 1.51) 0.76 (0.51; 1.13) 0.76 (0.50; 1.15) 0.99 (0.65; 1.50) 0.566
– high riske (n¼8507) 1 0.95 (0.71; 1.26) 0.76 (0.57; 1.02) 0.88 (0.66; 1.17) 0.88 (0.64; 1.19) 0.322
– at least 3 days diary (n¼12,815) 1 0.97 (0.73; 1.28) 0.79 (0.60; 1.05) 0.90 (0.68; 1.20) 0.86 (0.64; 1.16) 0.280
All cause
mortality
(2657)
Person-Years 3479 34597 34801 34652 35037
Incidents 437 582 587 586 465
Model 1b 1 1.01 (0.86; 1.17) 0.90 (0.77; 1.05) 0.99 (0.85; 1.16) 1.01 (0.85; 1.18) 0.981
Model 2c 1 1.00 (0.86; 1.18) 0.86 (0.74; 1.01) 0.95 (0.81; 1.12) 0.92 (0.78; 1.09) 0.262
– healthy at baselined (n¼10,795) 1 1.04 (0.85; 1.26) 0.82 (0.67; 1.00) 0.86 (0.70; 1.06) 0.98 (0.79; 1.20) 0.388
– high riske (n¼8507) 1 1.04 (0.88; 1.24) 0.88 (0.74; 1.05) 0.95 (0.80; 1.14) 1.00 (0.83; 1.20) 0.702
– at least 3 days diary (n¼12,815) 1 1.02 (0.87; 1.19) 0.87 (0.74; 1.02) 0.94 (0.80; 1.11) 0.93 (0.79; 1.10) 0.254
Postmenopausal Women (n¼8176)
CVD incidence
(3306)
Person-Years 18648 18517 18397 18323 18724
Incidents 632 644 702 683 645
Model 1b 1 0.91 (0.82; 1.02) 0.96 (0.86; 1.07) 1.03 (0.92; 1.15) 1.02 (0.91; 1.14) 0.266
Model 2c 1 0.89 (0.80; 0.99) 0.92 (0.83; 1.03) 0.99 (0.89; 1.11) 0.94 (0.84; 1.05) 0.793
– healthy at baselined (n¼5891) 1 0.94 (0.82; 1.09) 0.87 (0.75; 1.01) 0.93 (0.80; 1.08) 1.00 (0.87; 1.16) 0.976
– high riske (n¼5998) 1 0.90 (0.80; 1.02) 0.94 (0.84; 1.06) 1.00 (0.89; 1.13) 0.95 (0.84; 1.08) 0.901
– at least 3 days diary (n¼7839) 1 0.89 (0.80; 1.00) 0.92 (0.83; 1.03) 0.99 (0.88; 1.11) 0.95 (0.84; 1.06) 0.818
IHD incidence
(1157)
Person-Years 20737 20796 20782 20578 21028
Incidents 218 226 250 259 204
Model 1b 1 0.94 (0.78; 1.13) 1.00 (0.84; 1.20) 1.15 (0.96; 1.38) 0.97 (0.80; 1.17) 0.620
Model 2c 1 0.90 (0.75; 1.09) 0.96 (0.80; 1.16) 1.05 (0.87; 1.26) 0.84 (0.69; 1.02) 0.292
– healthy at baselined (n¼5891) 1 1.05 (0.80; 1.38) 0.92 (0.70; 1.21) 1.10 (0.84; 1.44) 0.94 (0.71; 1.24) 0.764
– high riske (n¼5998) 1 0.92 (0.75; 1.12) 0.97 (0.79; 1.18) 1.06 (0.87; 1.29) 0.88 (0.72; 1.09) 0.551
– at least 3 days diary (n¼7839) 1 0.93 (0.76; 1.12) 0.97 (0.80; 1.17) 1.05 (0.87; 1.27) 0.85 (0.70; 1.04) 0.311
Stroke incidence
(5 5 0)
Person-Years 21517 21509 21576 21538 21685
Incidents 110 119 115 107 99
Model 1b 1 0.90 (0.69; 1.17) 0.81 (0.62; 1.05) 0.84 (0.64; 1.10) 0.89 (0.67; 1.16) 0.316
Model 2c 1 0.89 (0.69; 1.16) 0.78 (0.60; 1.02) 0.79 (0.60; 1.04) 0.78 (0.59; 1.03) 0.054
– healthy at baselined (n¼5891) 1 0.92 (0.63; 1.33) 0.88 (0.61; 1.27) 0.87 (0.60; 1.26) 0.88 (0.60; 1.30) 0.494
– high riske (n¼5998) 1 0.95 (0.71; 1.25) 0.79 (0.59; 1.05) 0.80 (0.60; 1.08) 0.83 (0.61; 1.11) 0.117
– at least 3 days diary (n¼7839) 1 0.93 (0.71; 1.22) 0.81 (0.62; 1.07) 0.80 (0.61; 1.06) 0.83 (0.62; 1.10) 0.109
CVD mortality
(7 7 6)
Person-Years 20488 20356 20554 20393 20753
Incidents 156 157 156 167 140
Model 1b 1 0.94 (0.72; 1.22) 0.77 (0.58; 1.01) 0.92 (0.70; 1.20) 0.89 (0.67; 1.18) 0.407
Model 2c 1 0.93 (0.72; 1.22) 0.73 (0.56; 0.97) 0.85 (0.65; 1.12) 0.80 (0.60; 1.06) 0.089
– healthy at baselined (n¼5891) 1 1.03 (0.70; 1.52) 0.73 (0.48; 1.09) 0.74 (0.48; 1.12) 0.92 (0.61; 1.39) 0.326
– high riske (n¼5998) 1 0.99 (0.74; 1.31) 0.73 (0.54; 0.98) 0.89 (0.66; 1.19) 0.87 (0.64; 1.17) 0.248
– at least 3 days diary (n¼7839) 1 1.03 (0.78; 1.36) 0.77 (0.58; 1.02) 0.88 (0.66; 1.17) 0.86 (0.64; 1.16) 0.182
All cause
mortality
(2329)
Person-Years 20488 20356 20554 20393 20753
Incidents 444 484 477 492 432
Model 1b 1 0.97 (0.83; 1.14) 0.85 (0.72; 1.00) 0.96 (0.82; 1.13) 0.97 (0.82; 1.14) 0.670
Model 2c 1 0.97 (0.83; 1.14) 0.83 (0.70; 0.98) 0.93 (0.79; 1.10) 0.89 (0.76; 1.06) 0.168
– healthy at baselined (n¼5891) 1 1.05 (0.85; 1.28) 0.74 (0.60; 0.92) 0.85 (0.69; 1.05) 0.91 (0.73; 1.13) 0.134
– high riske (n¼5998) 1 0.99 (0.83; 1.18) 0.86 (0.72; 1.03) 0.95 (0.79; 1.13) 0.95 (0.79; 1.142) 0.502
– at least 3 days diary (n¼7839) 1 1.01 (0.86; 1.19) 0.86 (0.73; 1.02) 0.94 (0.79; 1.11) 0.93 (0.78; 1.10) 0.263
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a modest reduction in salt intake [41]. Projections based on the
DASH diet and data from NHANES estimate that such a reduction in
blood pressure could translate into approximately 3–4% fewer CHD
events over 10 years [42]. However, a direct comparison of results
from intervention studies with data from this study is limited
because observational epidemiological studies investigate by their
very nature chronic effects, whereas most intervention studies
focused on acute and subacute effects (see Supplemental Table 5
for a summary of dietary intervention studies), and there is a
paucity of data on chronic effects. There is also considerable
ambiguity regarding the type of ﬂavan-3-ols used. While in obser-
vational studies all but one, the Iowa Women's Health Study [17],
used ﬂavan-3-ol monomers as deﬁned here (Table 1); this is
different for dietary intervention studies. In some intervention
studies, ﬂavan-3-ols are not characterized by compound-speciﬁc
analyses, but only by their source. However, differences in growing
conditions, harvesting, processing, and storage can result in a large
variation of ﬂavan-3-ol content in foods [43–46]. For these reasons,
the actual ﬂavan-3-ol contents, and their relative composition, are
often not known. This is particularly important because so far only
the intake of one member of the cocoa ﬂavanol group, ()-epica-
techin, has directly and causally been linked to the modulation of
vascular function [7,8]. The absorption of oligomeric proanthocya-
nidins, important constituents of cocoa ﬂavanols and grape seed
extracts, is negligible and they do not contribute to the pool of
ﬂavan-3-ol metabolites [47].
Using food composition tables, we have estimated the ()-epi-
catechin intake in dietary intervention studies, assuming that
cocoa ﬂavanols consist of approximately 10% ()-epicatechin, 7%
(þ)-catechin, and 83% proanthocyanidins (DP 2–10). A compar-
ison of intakes used in intervention studies and the intake of the
population in EPIC-Norfolk (Fig. 5) shows clearly that intakes
in most studies were considerably higher, and it is likely that
()-epicatechin consumption in EPIC-Norfolk, and other cohorts,
is too low to have an effect on overall CVD risk. Indeed, a recent
meta-analysis has suggested that an effect on systolic blood
pressure can only be observed with intakes in excess of 50 mg/d
[9] of ()-epicatechin, but more than 90% of the EPIC-Norfolk
population do not consume this much, even though the Norfolk
cohort of EPIC has the highest ()-epicatechin intake of all EPIC
cohorts [25] and participants consume considerably more than the
general European public (mean intake in the EU: 13.5 mg/d) [23].
A comparison of mean ()-epicatechin in different European
countries with age-adjusted CHD mortality does not suggest a
signiﬁcant association (Fig. 6). These data suggest that ()-epicatechin
intake in the general public is too low to achieve an overall reduction
of cardiovascular disease risk.
In 2012, EFSA approved a health claim for cocoa ﬂavanols,
based on an unspeciﬁed degree of increase in ﬂow-mediated
dilation (FMD) [48] after cocoa ﬂavanol intake. The scientiﬁc
opinion underlying this claim states that 200 mg/d of cocoa
ﬂavanols can achieve improved vascular function. Independent
of these ﬁndings, studies have shown that a FMD increase of 1 to
1.5% could translate in a reduction of CVD events by 10% [49], and
such a reduction has been achieved in dietary intervention studies
with cocoa ﬂavanols [9]. In EPIC-Norfolk, approximately 25% of
participants consumed 200 mg/d or more of cocoa ﬂavanols.
However, there was no signiﬁcant difference in CVD risk between
those who met the 200 mg/d recommendation and those who did
not (HR 0.97; 95% CI: 0.89; 1.04 for men; HR 0.96; 95% CI: 0.89;
1.05 for women). When basing the intake recommendation on the
known bioactive constituent of cocoa ﬂavanols, ()-epicatechin,
more than 70% of participants met or exceed the recommenda-
tions of 20 mg/d. We observed no statistically signiﬁcant associa-
tion between intake above 20 mg/d and CVD risk in women (HR
1.00; 95% CI: 0.94; 1.08). However, this analysis is more complex in
a
M
is
si
n
g
va
lu
es
w
er
e
as
su
m
ed
to
be
m
is
si
n
g
at
ra
n
d
om
an
d
w
er
e
im
p
u
te
d
u
si
n
g
m
u
lt
ip
le
im
p
u
ta
ti
on
(n
¼
5)
w
it
h
u
n
iv
ar
ia
te
re
gr
es
si
on
m
od
el
s.
b
A
d
ju
st
ed
fo
r
B
M
I
an
d
en
er
gy
in
ta
ke
.
c
ad
ju
st
ed
fo
r
B
M
I,
en
er
gy
in
ta
ke
,
sy
st
ol
ic
bl
oo
d
p
re
ss
u
re
,
p
la
sm
a
ch
ol
es
te
ro
l,
p
la
sm
a
vi
ta
m
in
C
,
in
ta
ke
of
ﬁ
be
r,
p
ot
as
si
u
m
,
so
d
iu
m
,
fa
t,
sa
tu
ra
te
d
fa
t,
an
d
al
co
h
ol
,
an
d
th
e
fo
llo
w
in
g
ca
te
go
ri
ca
l
va
ri
ab
le
s—
p
hy
si
ca
l
ac
ti
vi
ty
,
sm
ok
in
g
st
at
u
s,
ed
u
ca
ti
on
,s
el
f-
re
p
or
te
d
h
is
to
ry
of
st
ro
ke
,m
yo
ca
rd
ia
l
in
fa
rc
ti
on
an
d
d
ia
be
te
s
at
ba
se
lin
e,
fa
m
ily
h
is
to
ry
of
m
yo
ca
rd
ia
l
in
fa
rc
ti
on
,u
se
of
an
ti
hy
p
er
te
n
si
ve
an
d
lip
id
lo
w
er
in
g
d
ru
gs
;
ad
d
it
io
n
al
ly
in
w
om
en
u
se
of
h
or
m
on
e
re
p
la
ce
m
en
t
th
er
ap
y.
d
In
cl
u
d
es
on
ly
p
ar
ti
ci
p
an
ts
w
it
h
ou
t
se
lf
-r
ep
or
te
d
h
is
to
ry
of
st
ro
ke
,m
yo
ca
rd
ia
l
in
fa
rc
t,
d
ia
be
te
s
m
el
lit
u
s,
fa
m
ily
h
is
to
ry
of
m
yo
ca
rd
ia
l
in
fa
rc
t,
an
d
n
o
u
se
of
an
ti
hy
p
er
te
n
si
ve
an
d
lip
id
-l
ow
er
in
g
d
ru
gs
.
e
In
cl
u
d
es
on
ly
p
ar
ti
ci
p
an
ts
w
it
h
a
10
-y
ea
r
C
V
D
ri
sk
20
%
h
ig
h
er
th
an
n
or
m
al
ba
se
d
on
d
at
a
fr
om
th
e
Fr
am
in
gh
am
H
ea
rt
St
u
d
y
(e
st
im
at
e
ba
se
d
on
Fr
am
in
gh
am
ri
sk
sc
or
e
u
si
n
g
ag
e,
se
x,
B
M
I,
an
d
bl
oo
d
p
re
ss
u
re
[3
6]
.
A. Vogiatzoglou et al. / Free Radical Biology and Medicine 84 (2015) 1–10 7
men as all participants with an ()-epicatechin intake of less than
20 mg/d are in the bottom quintile of ()-epicatechin and ﬂavan-
3-ol monomer intake. The small, but signiﬁcant, association
between CVD risk and ()-epicatechin intake found for men (HR
0.92; 95% CI: 0.86; 0.99) could therefore also be explained by
differences in dietary patterns as discussed above and needs to be
conﬁrmed in further studies.
Many dietary recommendations focus primarily on the preven-
tion of deﬁciency diseases [1], but there is an increasing interest in
also focusing on bioactives in the context of disease risk reduction
and primary prevention [50]. There is accumulating evidence for
the vasculoprotective effect of dietary ﬂavan-3-ols and the
observed effect on vascular function suggests that an adequate
intake could result in a 10% reduction of CVD risk in the general
public. This has important implications in the context of primary
prevention of CVD and evidence-based dietary recommendations.
So far, it is not yet clear what an adequate intake is: neither is it
clear whether it should be based on individual compounds, such
as ()-epicatechin, or a group of compounds such as cocoa
ﬂavanols, nor is it clear which amount should be recommended.
Fig. 3. Association between ﬂavan-3-ol intake and risk of CVD in 11,253 men (a) and 13634 women (b) of EPIC-Norfolk. This ﬁgure shows HR (95% CI) estimated using the
parsimonious model and quintiles of intake of each respective ﬂavan-3-ol group.
Fig. 4. Association between ﬂavan-3-ol intake and incidence of CVD in observational epidemiological studies conducted previously. Data show the estimated HR (95% CI)
comparing the bottom and top quintile of intake. Studies included: Zutphen Elderly Study [20]; EPIC-Norfolk (this study); HPFS: Health-Professional Follow-Up Study [15];
CPS: Cancer Prevention Study II [18]; IWH: Iowa Women's Health Study [17]; NHS I and II: Nurses Health Study [15]. Data for IHD and CHD were combined.
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Nevertheless, the data presented here clearly show that the
habitual intake in Europe or the United States is unlikely to have
any signiﬁcant effect on CVD risk on a population basis. Indeed, for
such a reduction to occur, an intake considerably higher than the
amount currently consumed by the general public is necessary.
Based on these data and previous investigations, it is essential
that new methods are developed that enable further research to
study more comprehensively the inﬂuences of age, sex, and
dietary background. Speciﬁcally in the context of observational
population-based studies, improved dietary assessment methods
are crucial for a better understanding of associations between
intake and CVD risk. Nutritional biomarkers can provide such
methods, but there is currently no commonly accepted, validated
biomarker of ﬂavan-3-ol intake, which meets the recommenda-
tions of the 2010 IOM biomarker report [51]. The short half-life
plasma in of structurally related ﬂavan-3-ol metabolites [52]
restricts their use to the assessment of acute intake. We have
hypothesized that ﬂavan-3-ol metabolites of the colonic micro-
biome, such as 5-(3,4-dihydroxyphenyl)-γ-valerolactone (γ-VL)
[53], which have a considerably longer biological half-life and
are present in higher concentrations [47], are more suitable as
nutritional biomarkers of ﬂavan-3-ol intake. In order to investigate
these compounds on a large scale, we have developed a validated
analytical method which can be automated for high-throughput
analysis. We are currently applying it to a cohort of approximately
25,000 participants to assess colonic metabolites as nutritional
biomarkers against the IOM criteria. Such a biomarker will then
allow us a much more accurate estimate of intake.
Only a combination of data from observational and interven-
tion studies will ultimately enable a comprehensive assessment of
the impact of ﬂavan-3-ol intake in the context of primary preven-
tion, public health and evidence-based dietary recommendations.
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